{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:53:41Z","timestamp":1700700821631},"reference-count":38,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2023.14109","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T10:28:56Z","timestamp":1697711336000},"source":"Crossref","is-referenced-by-count":0,"title":["Cancer of unknown primary histologically, genetically and spatially diagnosed as left ovary\u2011derived cancer: A case report"],"prefix":"10.3892","volume":"26","author":[{"given":"Harunori","family":"Honjoh","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113 8655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumi","family":"Taguchi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113 8655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Rokutan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo 113 8655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113 8655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo 113 8655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Nishijima","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113 8655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Eguchi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113 8655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113 8655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenbun","family":"Sone","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113 8655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayuyo","family":"Uchino\u2011Mori","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113 8655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Osuga","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113 8655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"key":"key20231122104217_b1-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1056\/NEJMra1303917","article-title":"Cancer of unknown primary site","volume":"371","author":"Varadhachary","year":"2014","journal-title":"N Engl J Med"},{"key":"key20231122104217_b2-ol-26-6-14109","first-page":"e5552","article-title":"Cancer of unknown primary: A review on clinical guidelines in the development and targeted management of patients with the unknown primary site","volume":"11","author":"Qaseem","year":"2019","journal-title":"Cureus"},{"key":"key20231122104217_b3-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.trecan.2020.11.002","article-title":"Cancer of unknown primary in the molecular Era","volume":"7","author":"Kato","year":"2021","journal-title":"Trends Cancer"},{"key":"key20231122104217_b4-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/S0140-6736(11)61178-1","article-title":"Cancer of unknown primary site","volume":"379","author":"Pavlidis","year":"2012","journal-title":"Lancet"},{"key":"key20231122104217_b5-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jare.2014.11.007","article-title":"A mini review on cancer of unknown primary site: A clinical puzzle for the oncologists","volume":"6","author":"Pavlidis","year":"2015","journal-title":"J Adv Res"},{"key":"key20231122104217_b6-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1016\/S0959-8049(03)00547-1","article-title":"Diagnostic and therapeutic management of cancer of an unknown primary","volume":"39","author":"Pavlidis","year":"2003","journal-title":"Eur J Cancer"},{"key":"key20231122104217_b7-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s41669-017-0051-2","article-title":"The potential clinical and economic value of primary tumour identification in metastatic cancer of unknown primary tumour: A population-based retrospective matched cohort study","volume":"2","author":"Hannouf","year":"2018","journal-title":"Pharmacoecon Open"},{"key":"key20231122104217_b8-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1186\/s12885-022-10472-z","article-title":"Clinical features of cancer with unknown primary site (clinical features, treatment, prognosis of cancer with unknown primary site)","volume":"22","author":"Yang","year":"2022","journal-title":"BMC Cancer"},{"key":"key20231122104217_b9-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1200\/JCO.2012.43.3755","article-title":"Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: A prospective trial of the Sarah Cannon research institute","volume":"31","author":"Hainsworth","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20231122104217_b10-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1093\/jnci\/djt099","article-title":"Molecular profiling diagnosis in unknown primary cancer: Accuracy and ability to complement standard pathology","volume":"105","author":"Greco","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"key20231122104217_b11-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1200\/JCO.2007.14.4378","article-title":"Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation","volume":"26","author":"Varadhachary","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20231122104217_b12-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.18.00771","article-title":"Randomized phase II trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site","volume":"37","author":"Hayashi","year":"2019","journal-title":"J Clin Oncol"},{"key":"key20231122104217_b13-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S1470-2045(16)30297-2","article-title":"Epigenetic profiling to classify cancer of unknown primary: A multicentre, retrospective analysis","volume":"17","author":"Moran","year":"2016","journal-title":"Lancet Oncol"},{"key":"key20231122104217_b14-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"666156","DOI":"10.3389\/fcell.2021.666156","article-title":"Genetic characterization of cancer of unknown primary using liquid biopsy approaches","volume":"9","author":"Laprovitera","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"key20231122104217_b15-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"e769","DOI":"10.1002\/onco.13744","article-title":"A challenging task: Identifying patients with cancer of unknown primary (CUP) According to ESMO Guidelines: The CUPISCO trial experience","volume":"26","author":"Pauli","year":"2021","journal-title":"Oncologist"},{"key":"key20231122104217_b16-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00428-022-03435-z","article-title":"Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs)","volume":"482","author":"Pisacane","year":"2023","journal-title":"Virchows Arch"},{"key":"key20231122104217_b17-ol-26-6-14109","first-page":"66","article-title":"Carcinomatous meningitis from ovarian serous carcinoma: A case report","volume":"25","author":"Uchikura","year":"2022","journal-title":"Oncol Lett"},{"key":"key20231122104217_b18-ol-26-6-14109","article-title":"Atlas of Exfoliative Cytology","author":"Papanicolaou","year":"1954"},{"key":"key20231122104217_b19-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.3390\/microorganisms8111776","article-title":"Exosomes of epstein-barr virus-associated gastric carcinoma suppress dendritic cell maturation","volume":"8","author":"Hinata","year":"2020","journal-title":"Microorganisms"},{"key":"key20231122104217_b20-ol-26-6-14109","volume":"Vol 4","author":"WHO Classification of Tumours Editorial Board","year":"2020","journal-title":"Female Genital Tumors, WHO Classification of Tumors"},{"key":"key20231122104217_b21-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/00125480-200607000-00004","article-title":"The diagnosis of malignancy in effusion cytology: A pattern recognition approach","volume":"13","author":"Pereira","year":"2006","journal-title":"Adv Anat Pathol"},{"key":"key20231122104217_b22-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"e0264138","DOI":"10.1371\/journal.pone.0264138","article-title":"Clinical and analytical validation of FoundationOne\u00ae CDx, a comprehensive genomic profiling assay for solid tumors","volume":"17","author":"Milbury","year":"2022","journal-title":"PLoS One"},{"key":"key20231122104217_b23-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"key20231122104217_b24-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"key20231122104217_b25-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"key":"key20231122104217_b26-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"102204","DOI":"10.1016\/j.ctrv.2021.102204","article-title":"Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?","volume":"97","author":"Olivier","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"key20231122104217_b27-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41416-018-0332-2","article-title":"Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the \u2018U\u2019 out of \u2018CUP\u2019","volume":"120","author":"Conway","year":"2019","journal-title":"Br J Cancer"},{"key":"key20231122104217_b28-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/S0735-6757(98)90141-3","article-title":"Pseudo-Meigs' Syndrome","volume":"16","author":"Kazanov","year":"1998","journal-title":"Am J Emerg Med"},{"key":"key20231122104217_b29-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.ygyno.2005.01.029","article-title":"Ovarian dysgerminoma associated with Pseudo-Meigs' syndrome and functioning ovarian stroma: A case report","volume":"97","author":"G\u00fccer","year":"2005","journal-title":"Gynecol Oncol"},{"key":"key20231122104217_b30-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"key20231122104217_b31-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"key20231122104217_b32-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.3802\/jgo.2019.30.e105","article-title":"How to use immune checkpoint inhibitor in ovarian cancer?","volume":"30","author":"Park","year":"2019","journal-title":"J Gynecol Oncol"},{"key":"key20231122104217_b33-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"17588359211039899","DOI":"10.1177\/17588359211039899","article-title":"Immune checkpoint inhibitors in ovarian cancer: Where do we stand?","volume":"13","author":"Leary","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"key20231122104217_b34-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/bs.ai.2016.01.001","article-title":"The role of neoantigens in naturally occurring and therapeutically induced immune responses to cancer","volume":"130","author":"Ward","year":"2016","journal-title":"Adv Immunol"},{"key":"key20231122104217_b35-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"e004822","DOI":"10.1136\/jitc-2022-004822","article-title":"Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): A phase 2 non-randomized clinical trial","volume":"10","author":"Raghav","year":"2022","journal-title":"J Immunother Cancer"},{"key":"key20231122104217_b36-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.annonc.2021.11.009","article-title":"Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary","volume":"33","author":"Tanizaki","year":"2022","journal-title":"Ann Oncol"},{"key":"key20231122104217_b37-ol-26-6-14109","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s40425-019-0720-z","article-title":"Clinical and immune profiling for cancer of unknown primary site","volume":"7","author":"Haratani","year":"2019","journal-title":"J Immunother Cancer"},{"key":"key20231122104217_b38-ol-26-6-14109","article-title":"Act on the Protection of Personal Information: Last Version: Act No. 37 of 2021","author":"Japanese government"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T08:46:47Z","timestamp":1700642807000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2023.14109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,10,19]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2023.14109","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,19]]},"article-number":"522"}}